Ascelia Pharma Management
Management criteria checks 2/4
Ascelia Pharma's CEO is Magnus Corfitzen, appointed in Jan 2014, has a tenure of 8.58 years. total yearly compensation is SEK14.88M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.82% of the company’s shares, worth SEK5.50M. The average tenure of the management team and the board of directors is 4.6 years and 5.6 years respectively.
Key information
Magnus Corfitzen
Chief executive officer
SEK 14.9m
Total compensation
| CEO salary percentage | 12.7% |
| CEO tenure | 8.6yrs |
| CEO ownership | 0.8% |
| Management average tenure | 4.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -SEK 115m |
| Mar 31 2022 | n/a | n/a | -SEK 126m |
| Dec 31 2021 | SEK 15m | SEK 2m | -SEK 126m |
| Sep 30 2021 | n/a | n/a | -SEK 127m |
| Jun 30 2021 | n/a | n/a | -SEK 113m |
| Mar 31 2021 | n/a | n/a | -SEK 111m |
| Dec 31 2020 | SEK 5m | SEK 2m | -SEK 99m |
| Sep 30 2020 | n/a | n/a | -SEK 90m |
| Jun 30 2020 | n/a | n/a | -SEK 88m |
| Mar 31 2020 | n/a | n/a | -SEK 71m |
| Dec 31 2019 | SEK 3m | SEK 992k | -SEK 66m |
| Sep 30 2019 | n/a | n/a | -SEK 46m |
| Jun 30 2019 | n/a | n/a | -SEK 37m |
| Mar 31 2019 | n/a | n/a | -SEK 30m |
| Dec 31 2018 | n/a | n/a | -SEK 23m |
| Sep 30 2018 | n/a | n/a | -SEK 22m |
| Jun 30 2018 | SEK 4m | SEK 1m | -SEK 24m |
Compensation vs Market: Magnus's total compensation ($USD1.40M) is above average for companies of similar size in the UK market ($USD348.41K).
Compensation vs Earnings: Magnus's compensation has increased whilst the company is unprofitable.
CEO
Magnus Corfitzen (47 yo)
8.6yrs
Tenure
SEK 14,875,000
Compensation
Mr. Magnus O. Corfitzen serves as the Chief Executive Officer at Ascelia Pharma AB since 2014. He serves as a Director of NsGene A/S. He serves as a Director of DentoFit A/S.Mr. Corfitzen serves on the bo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 8.6yrs | SEK 14.88m | 0.82% SEK 5.5m | |
| Chief Financial Officer | 5.6yrs | no data | 0.055% SEK 372.2k | |
| Chief Scientific Officer and Scientific Director | no data | no data | no data | |
| Head of IR & Communications | 4.6yrs | no data | 0.0089% SEK 59.9k | |
| Chief Medical Officer | 3.8yrs | no data | 0.18% SEK 1.2m | |
| Chief Commercial Officer | 2.6yrs | no data | 0.12% SEK 833.2k | |
| Vice President of Research & Development | no data | no data | no data |
4.6yrs
Average Tenure
54.5yo
Average Age
Experienced Management: ACES's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board of Directors | 5.6yrs | SEK 490.00k | 0.065% SEK 439.5k | |
| Independent Director | 22.6yrs | SEK 258.00k | 0.81% SEK 5.4m | |
| Independent Director | 5.6yrs | SEK 258.00k | 0.059% SEK 399.6k | |
| Independent Director | 2.3yrs | SEK 333.00k | no data | |
| Independent Director | 5.6yrs | SEK 333.00k | 0.053% SEK 359.6k | |
| Independent Director | 5.6yrs | SEK 233.00k | 3% SEK 20.2m |
5.6yrs
Average Tenure
67yo
Average Age
Experienced Board: ACES's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/31 17:11 |
| End of Day Share Price | 2022/06/03 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Ludvig Svensson | Penser Access |
| Johan Unnerus | Redeye |